Publication of the 2021 Annual Financial Report
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Paris (France), April 28, 2022 – 6.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]
Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]
Extraordinary General Meeting (April 19, 2020 | 2:00 pm)
AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]
AACR Annual Meeting 2022 (April 8 – 13, 2022)
Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]
Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Paris (France), March 9, 2022 – 7:00 […]